First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer
Background Treatment with an oral fluoropyrimidine plus cisplatin is widely used for advanced gastric cancer, but patients with severe peritoneal metastasis often cannot tolerate such treatment, due to inadequate oral intake or massive ascites. The aim of this study was to assess the efficacy and sa...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Iwasa, Satoru [verfasserIn] Nakajima, Takako Eguchi [verfasserIn] Nakamura, Kenichi [verfasserIn] Takashima, Atsuo [verfasserIn] Kato, Ken [verfasserIn] Hamaguchi, Tetsuya [verfasserIn] Yamada, Yasuhide [verfasserIn] Shimada, Yasuhiro [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2011 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Gastric Cancer - Springer-Verlag, 2002, 15(2011), 1 vom: 15. Mai, Seite 21-26 |
|---|---|
| Übergeordnetes Werk: |
volume:15 ; year:2011 ; number:1 ; day:15 ; month:05 ; pages:21-26 |
| Links: |
|---|
| DOI / URN: |
10.1007/s10120-011-0056-y |
|---|
| Katalog-ID: |
SPR009317430 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR009317430 | ||
| 003 | DE-627 | ||
| 005 | 20201124064103.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201005s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10120-011-0056-y |2 doi | |
| 035 | |a (DE-627)SPR009317430 | ||
| 035 | |a (SPR)s10120-011-0056-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Iwasa, Satoru |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background Treatment with an oral fluoropyrimidine plus cisplatin is widely used for advanced gastric cancer, but patients with severe peritoneal metastasis often cannot tolerate such treatment, due to inadequate oral intake or massive ascites. The aim of this study was to assess the efficacy and safety of systemic chemotherapy for advanced gastric cancer with severe peritoneal metastasis. Methods The cases of 92 patients with advanced gastric cancer and severe peritoneal metastasis who received first-line chemotherapy at our hospital between May 2001 and February 2007 were retrospectively analyzed. Severe peritoneal metastasis was defined as massive ascites or inadequate oral intake due to peritoneal dissemination. Inadequate oral intake was defined as having required an intravenous drip infusion. Results All 92 patients received 5-fluorouracil (5-FU)-based chemotherapy; 40 of the patients had massive ascites, 34 had inadequate oral intake, and the remaining 18 had both conditions. Among the 86 patients having assessable ascites, 23 (27%) patients showed an improvement in ascites. Of the 52 patients with inadequate oral intake, 17 (33%) patients improved to the point of ingesting without intravenous drip infusion after receiving the chemotherapy. Median time to treatment failure and overall survival time were 1.9 months [95% confidence interval (CI) 1.3–2.5 months] and 4.6 months (95% CI 3.9–5.3 months), respectively. Major grade 3 or 4 adverse events were anorexia (26%), neutropenia (26%), and anemia (22%). Conclusion The treatment regimen of 5-FU-based chemotherapy for advanced gastric cancer with severe peritoneal metastasis was feasible, but its efficacy was not sufficient. | ||
| 650 | 4 | |a Gastric cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Peritoneal metastasis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ascites |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Oral intake |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Nakajima, Takako Eguchi |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Kenichi |e verfasserin |4 aut | |
| 700 | 1 | |a Takashima, Atsuo |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Hamaguchi, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Yasuhide |e verfasserin |4 aut | |
| 700 | 1 | |a Shimada, Yasuhiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastric Cancer |d Springer-Verlag, 2002 |g 15(2011), 1 vom: 15. Mai, Seite 21-26 |w (DE-627)SPR009286586 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2011 |g number:1 |g day:15 |g month:05 |g pages:21-26 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10120-011-0056-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2011 |e 1 |b 15 |c 05 |h 21-26 | ||
| author_variant |
s i si t e n te ten k n kn a t at k k kk t h th y y yy y s ys |
|---|---|
| matchkey_str |
iwasasatorunakajimatakakoeguchinakamurak:2011----:islnfuruaibsdhmteayoptetwtsvrprtna |
| hierarchy_sort_str |
2011 |
| publishDate |
2011 |
| allfields |
10.1007/s10120-011-0056-y doi (DE-627)SPR009317430 (SPR)s10120-011-0056-y-e DE-627 ger DE-627 rakwb eng Iwasa, Satoru verfasserin aut First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Treatment with an oral fluoropyrimidine plus cisplatin is widely used for advanced gastric cancer, but patients with severe peritoneal metastasis often cannot tolerate such treatment, due to inadequate oral intake or massive ascites. The aim of this study was to assess the efficacy and safety of systemic chemotherapy for advanced gastric cancer with severe peritoneal metastasis. Methods The cases of 92 patients with advanced gastric cancer and severe peritoneal metastasis who received first-line chemotherapy at our hospital between May 2001 and February 2007 were retrospectively analyzed. Severe peritoneal metastasis was defined as massive ascites or inadequate oral intake due to peritoneal dissemination. Inadequate oral intake was defined as having required an intravenous drip infusion. Results All 92 patients received 5-fluorouracil (5-FU)-based chemotherapy; 40 of the patients had massive ascites, 34 had inadequate oral intake, and the remaining 18 had both conditions. Among the 86 patients having assessable ascites, 23 (27%) patients showed an improvement in ascites. Of the 52 patients with inadequate oral intake, 17 (33%) patients improved to the point of ingesting without intravenous drip infusion after receiving the chemotherapy. Median time to treatment failure and overall survival time were 1.9 months [95% confidence interval (CI) 1.3–2.5 months] and 4.6 months (95% CI 3.9–5.3 months), respectively. Major grade 3 or 4 adverse events were anorexia (26%), neutropenia (26%), and anemia (22%). Conclusion The treatment regimen of 5-FU-based chemotherapy for advanced gastric cancer with severe peritoneal metastasis was feasible, but its efficacy was not sufficient. Gastric cancer (dpeaa)DE-He213 Peritoneal metastasis (dpeaa)DE-He213 Ascites (dpeaa)DE-He213 Oral intake (dpeaa)DE-He213 Nakajima, Takako Eguchi verfasserin aut Nakamura, Kenichi verfasserin aut Takashima, Atsuo verfasserin aut Kato, Ken verfasserin aut Hamaguchi, Tetsuya verfasserin aut Yamada, Yasuhide verfasserin aut Shimada, Yasuhiro verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 15(2011), 1 vom: 15. Mai, Seite 21-26 (DE-627)SPR009286586 nnns volume:15 year:2011 number:1 day:15 month:05 pages:21-26 https://dx.doi.org/10.1007/s10120-011-0056-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 15 2011 1 15 05 21-26 |
| spelling |
10.1007/s10120-011-0056-y doi (DE-627)SPR009317430 (SPR)s10120-011-0056-y-e DE-627 ger DE-627 rakwb eng Iwasa, Satoru verfasserin aut First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Treatment with an oral fluoropyrimidine plus cisplatin is widely used for advanced gastric cancer, but patients with severe peritoneal metastasis often cannot tolerate such treatment, due to inadequate oral intake or massive ascites. The aim of this study was to assess the efficacy and safety of systemic chemotherapy for advanced gastric cancer with severe peritoneal metastasis. Methods The cases of 92 patients with advanced gastric cancer and severe peritoneal metastasis who received first-line chemotherapy at our hospital between May 2001 and February 2007 were retrospectively analyzed. Severe peritoneal metastasis was defined as massive ascites or inadequate oral intake due to peritoneal dissemination. Inadequate oral intake was defined as having required an intravenous drip infusion. Results All 92 patients received 5-fluorouracil (5-FU)-based chemotherapy; 40 of the patients had massive ascites, 34 had inadequate oral intake, and the remaining 18 had both conditions. Among the 86 patients having assessable ascites, 23 (27%) patients showed an improvement in ascites. Of the 52 patients with inadequate oral intake, 17 (33%) patients improved to the point of ingesting without intravenous drip infusion after receiving the chemotherapy. Median time to treatment failure and overall survival time were 1.9 months [95% confidence interval (CI) 1.3–2.5 months] and 4.6 months (95% CI 3.9–5.3 months), respectively. Major grade 3 or 4 adverse events were anorexia (26%), neutropenia (26%), and anemia (22%). Conclusion The treatment regimen of 5-FU-based chemotherapy for advanced gastric cancer with severe peritoneal metastasis was feasible, but its efficacy was not sufficient. Gastric cancer (dpeaa)DE-He213 Peritoneal metastasis (dpeaa)DE-He213 Ascites (dpeaa)DE-He213 Oral intake (dpeaa)DE-He213 Nakajima, Takako Eguchi verfasserin aut Nakamura, Kenichi verfasserin aut Takashima, Atsuo verfasserin aut Kato, Ken verfasserin aut Hamaguchi, Tetsuya verfasserin aut Yamada, Yasuhide verfasserin aut Shimada, Yasuhiro verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 15(2011), 1 vom: 15. Mai, Seite 21-26 (DE-627)SPR009286586 nnns volume:15 year:2011 number:1 day:15 month:05 pages:21-26 https://dx.doi.org/10.1007/s10120-011-0056-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 15 2011 1 15 05 21-26 |
| allfields_unstemmed |
10.1007/s10120-011-0056-y doi (DE-627)SPR009317430 (SPR)s10120-011-0056-y-e DE-627 ger DE-627 rakwb eng Iwasa, Satoru verfasserin aut First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Treatment with an oral fluoropyrimidine plus cisplatin is widely used for advanced gastric cancer, but patients with severe peritoneal metastasis often cannot tolerate such treatment, due to inadequate oral intake or massive ascites. The aim of this study was to assess the efficacy and safety of systemic chemotherapy for advanced gastric cancer with severe peritoneal metastasis. Methods The cases of 92 patients with advanced gastric cancer and severe peritoneal metastasis who received first-line chemotherapy at our hospital between May 2001 and February 2007 were retrospectively analyzed. Severe peritoneal metastasis was defined as massive ascites or inadequate oral intake due to peritoneal dissemination. Inadequate oral intake was defined as having required an intravenous drip infusion. Results All 92 patients received 5-fluorouracil (5-FU)-based chemotherapy; 40 of the patients had massive ascites, 34 had inadequate oral intake, and the remaining 18 had both conditions. Among the 86 patients having assessable ascites, 23 (27%) patients showed an improvement in ascites. Of the 52 patients with inadequate oral intake, 17 (33%) patients improved to the point of ingesting without intravenous drip infusion after receiving the chemotherapy. Median time to treatment failure and overall survival time were 1.9 months [95% confidence interval (CI) 1.3–2.5 months] and 4.6 months (95% CI 3.9–5.3 months), respectively. Major grade 3 or 4 adverse events were anorexia (26%), neutropenia (26%), and anemia (22%). Conclusion The treatment regimen of 5-FU-based chemotherapy for advanced gastric cancer with severe peritoneal metastasis was feasible, but its efficacy was not sufficient. Gastric cancer (dpeaa)DE-He213 Peritoneal metastasis (dpeaa)DE-He213 Ascites (dpeaa)DE-He213 Oral intake (dpeaa)DE-He213 Nakajima, Takako Eguchi verfasserin aut Nakamura, Kenichi verfasserin aut Takashima, Atsuo verfasserin aut Kato, Ken verfasserin aut Hamaguchi, Tetsuya verfasserin aut Yamada, Yasuhide verfasserin aut Shimada, Yasuhiro verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 15(2011), 1 vom: 15. Mai, Seite 21-26 (DE-627)SPR009286586 nnns volume:15 year:2011 number:1 day:15 month:05 pages:21-26 https://dx.doi.org/10.1007/s10120-011-0056-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 15 2011 1 15 05 21-26 |
| allfieldsGer |
10.1007/s10120-011-0056-y doi (DE-627)SPR009317430 (SPR)s10120-011-0056-y-e DE-627 ger DE-627 rakwb eng Iwasa, Satoru verfasserin aut First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Treatment with an oral fluoropyrimidine plus cisplatin is widely used for advanced gastric cancer, but patients with severe peritoneal metastasis often cannot tolerate such treatment, due to inadequate oral intake or massive ascites. The aim of this study was to assess the efficacy and safety of systemic chemotherapy for advanced gastric cancer with severe peritoneal metastasis. Methods The cases of 92 patients with advanced gastric cancer and severe peritoneal metastasis who received first-line chemotherapy at our hospital between May 2001 and February 2007 were retrospectively analyzed. Severe peritoneal metastasis was defined as massive ascites or inadequate oral intake due to peritoneal dissemination. Inadequate oral intake was defined as having required an intravenous drip infusion. Results All 92 patients received 5-fluorouracil (5-FU)-based chemotherapy; 40 of the patients had massive ascites, 34 had inadequate oral intake, and the remaining 18 had both conditions. Among the 86 patients having assessable ascites, 23 (27%) patients showed an improvement in ascites. Of the 52 patients with inadequate oral intake, 17 (33%) patients improved to the point of ingesting without intravenous drip infusion after receiving the chemotherapy. Median time to treatment failure and overall survival time were 1.9 months [95% confidence interval (CI) 1.3–2.5 months] and 4.6 months (95% CI 3.9–5.3 months), respectively. Major grade 3 or 4 adverse events were anorexia (26%), neutropenia (26%), and anemia (22%). Conclusion The treatment regimen of 5-FU-based chemotherapy for advanced gastric cancer with severe peritoneal metastasis was feasible, but its efficacy was not sufficient. Gastric cancer (dpeaa)DE-He213 Peritoneal metastasis (dpeaa)DE-He213 Ascites (dpeaa)DE-He213 Oral intake (dpeaa)DE-He213 Nakajima, Takako Eguchi verfasserin aut Nakamura, Kenichi verfasserin aut Takashima, Atsuo verfasserin aut Kato, Ken verfasserin aut Hamaguchi, Tetsuya verfasserin aut Yamada, Yasuhide verfasserin aut Shimada, Yasuhiro verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 15(2011), 1 vom: 15. Mai, Seite 21-26 (DE-627)SPR009286586 nnns volume:15 year:2011 number:1 day:15 month:05 pages:21-26 https://dx.doi.org/10.1007/s10120-011-0056-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 15 2011 1 15 05 21-26 |
| allfieldsSound |
10.1007/s10120-011-0056-y doi (DE-627)SPR009317430 (SPR)s10120-011-0056-y-e DE-627 ger DE-627 rakwb eng Iwasa, Satoru verfasserin aut First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Treatment with an oral fluoropyrimidine plus cisplatin is widely used for advanced gastric cancer, but patients with severe peritoneal metastasis often cannot tolerate such treatment, due to inadequate oral intake or massive ascites. The aim of this study was to assess the efficacy and safety of systemic chemotherapy for advanced gastric cancer with severe peritoneal metastasis. Methods The cases of 92 patients with advanced gastric cancer and severe peritoneal metastasis who received first-line chemotherapy at our hospital between May 2001 and February 2007 were retrospectively analyzed. Severe peritoneal metastasis was defined as massive ascites or inadequate oral intake due to peritoneal dissemination. Inadequate oral intake was defined as having required an intravenous drip infusion. Results All 92 patients received 5-fluorouracil (5-FU)-based chemotherapy; 40 of the patients had massive ascites, 34 had inadequate oral intake, and the remaining 18 had both conditions. Among the 86 patients having assessable ascites, 23 (27%) patients showed an improvement in ascites. Of the 52 patients with inadequate oral intake, 17 (33%) patients improved to the point of ingesting without intravenous drip infusion after receiving the chemotherapy. Median time to treatment failure and overall survival time were 1.9 months [95% confidence interval (CI) 1.3–2.5 months] and 4.6 months (95% CI 3.9–5.3 months), respectively. Major grade 3 or 4 adverse events were anorexia (26%), neutropenia (26%), and anemia (22%). Conclusion The treatment regimen of 5-FU-based chemotherapy for advanced gastric cancer with severe peritoneal metastasis was feasible, but its efficacy was not sufficient. Gastric cancer (dpeaa)DE-He213 Peritoneal metastasis (dpeaa)DE-He213 Ascites (dpeaa)DE-He213 Oral intake (dpeaa)DE-He213 Nakajima, Takako Eguchi verfasserin aut Nakamura, Kenichi verfasserin aut Takashima, Atsuo verfasserin aut Kato, Ken verfasserin aut Hamaguchi, Tetsuya verfasserin aut Yamada, Yasuhide verfasserin aut Shimada, Yasuhiro verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 15(2011), 1 vom: 15. Mai, Seite 21-26 (DE-627)SPR009286586 nnns volume:15 year:2011 number:1 day:15 month:05 pages:21-26 https://dx.doi.org/10.1007/s10120-011-0056-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 15 2011 1 15 05 21-26 |
| language |
English |
| source |
Enthalten in Gastric Cancer 15(2011), 1 vom: 15. Mai, Seite 21-26 volume:15 year:2011 number:1 day:15 month:05 pages:21-26 |
| sourceStr |
Enthalten in Gastric Cancer 15(2011), 1 vom: 15. Mai, Seite 21-26 volume:15 year:2011 number:1 day:15 month:05 pages:21-26 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Gastric cancer Peritoneal metastasis Ascites Oral intake |
| isfreeaccess_bool |
false |
| container_title |
Gastric Cancer |
| authorswithroles_txt_mv |
Iwasa, Satoru @@aut@@ Nakajima, Takako Eguchi @@aut@@ Nakamura, Kenichi @@aut@@ Takashima, Atsuo @@aut@@ Kato, Ken @@aut@@ Hamaguchi, Tetsuya @@aut@@ Yamada, Yasuhide @@aut@@ Shimada, Yasuhiro @@aut@@ |
| publishDateDaySort_date |
2011-05-15T00:00:00Z |
| hierarchy_top_id |
SPR009286586 |
| id |
SPR009317430 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009317430</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20201124064103.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2011 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10120-011-0056-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009317430</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10120-011-0056-y-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Iwasa, Satoru</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Treatment with an oral fluoropyrimidine plus cisplatin is widely used for advanced gastric cancer, but patients with severe peritoneal metastasis often cannot tolerate such treatment, due to inadequate oral intake or massive ascites. The aim of this study was to assess the efficacy and safety of systemic chemotherapy for advanced gastric cancer with severe peritoneal metastasis. Methods The cases of 92 patients with advanced gastric cancer and severe peritoneal metastasis who received first-line chemotherapy at our hospital between May 2001 and February 2007 were retrospectively analyzed. Severe peritoneal metastasis was defined as massive ascites or inadequate oral intake due to peritoneal dissemination. Inadequate oral intake was defined as having required an intravenous drip infusion. Results All 92 patients received 5-fluorouracil (5-FU)-based chemotherapy; 40 of the patients had massive ascites, 34 had inadequate oral intake, and the remaining 18 had both conditions. Among the 86 patients having assessable ascites, 23 (27%) patients showed an improvement in ascites. Of the 52 patients with inadequate oral intake, 17 (33%) patients improved to the point of ingesting without intravenous drip infusion after receiving the chemotherapy. Median time to treatment failure and overall survival time were 1.9 months [95% confidence interval (CI) 1.3–2.5 months] and 4.6 months (95% CI 3.9–5.3 months), respectively. Major grade 3 or 4 adverse events were anorexia (26%), neutropenia (26%), and anemia (22%). Conclusion The treatment regimen of 5-FU-based chemotherapy for advanced gastric cancer with severe peritoneal metastasis was feasible, but its efficacy was not sufficient.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastric cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peritoneal metastasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ascites</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oral intake</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakajima, Takako Eguchi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakamura, Kenichi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takashima, Atsuo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kato, Ken</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamaguchi, Tetsuya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamada, Yasuhide</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shimada, Yasuhiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Gastric Cancer</subfield><subfield code="d">Springer-Verlag, 2002</subfield><subfield code="g">15(2011), 1 vom: 15. Mai, Seite 21-26</subfield><subfield code="w">(DE-627)SPR009286586</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2011</subfield><subfield code="g">number:1</subfield><subfield code="g">day:15</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:21-26</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10120-011-0056-y</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2011</subfield><subfield code="e">1</subfield><subfield code="b">15</subfield><subfield code="c">05</subfield><subfield code="h">21-26</subfield></datafield></record></collection>
|
| author |
Iwasa, Satoru |
| spellingShingle |
Iwasa, Satoru misc Gastric cancer misc Peritoneal metastasis misc Ascites misc Oral intake First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer |
| authorStr |
Iwasa, Satoru |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR009286586 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer Gastric cancer (dpeaa)DE-He213 Peritoneal metastasis (dpeaa)DE-He213 Ascites (dpeaa)DE-He213 Oral intake (dpeaa)DE-He213 |
| topic |
misc Gastric cancer misc Peritoneal metastasis misc Ascites misc Oral intake |
| topic_unstemmed |
misc Gastric cancer misc Peritoneal metastasis misc Ascites misc Oral intake |
| topic_browse |
misc Gastric cancer misc Peritoneal metastasis misc Ascites misc Oral intake |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Gastric Cancer |
| hierarchy_parent_id |
SPR009286586 |
| hierarchy_top_title |
Gastric Cancer |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR009286586 |
| title |
First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer |
| ctrlnum |
(DE-627)SPR009317430 (SPR)s10120-011-0056-y-e |
| title_full |
First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer |
| author_sort |
Iwasa, Satoru |
| journal |
Gastric Cancer |
| journalStr |
Gastric Cancer |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2011 |
| contenttype_str_mv |
txt |
| container_start_page |
21 |
| author_browse |
Iwasa, Satoru Nakajima, Takako Eguchi Nakamura, Kenichi Takashima, Atsuo Kato, Ken Hamaguchi, Tetsuya Yamada, Yasuhide Shimada, Yasuhiro |
| container_volume |
15 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Iwasa, Satoru |
| doi_str_mv |
10.1007/s10120-011-0056-y |
| author2-role |
verfasserin |
| title_sort |
first-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer |
| title_auth |
First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer |
| abstract |
Background Treatment with an oral fluoropyrimidine plus cisplatin is widely used for advanced gastric cancer, but patients with severe peritoneal metastasis often cannot tolerate such treatment, due to inadequate oral intake or massive ascites. The aim of this study was to assess the efficacy and safety of systemic chemotherapy for advanced gastric cancer with severe peritoneal metastasis. Methods The cases of 92 patients with advanced gastric cancer and severe peritoneal metastasis who received first-line chemotherapy at our hospital between May 2001 and February 2007 were retrospectively analyzed. Severe peritoneal metastasis was defined as massive ascites or inadequate oral intake due to peritoneal dissemination. Inadequate oral intake was defined as having required an intravenous drip infusion. Results All 92 patients received 5-fluorouracil (5-FU)-based chemotherapy; 40 of the patients had massive ascites, 34 had inadequate oral intake, and the remaining 18 had both conditions. Among the 86 patients having assessable ascites, 23 (27%) patients showed an improvement in ascites. Of the 52 patients with inadequate oral intake, 17 (33%) patients improved to the point of ingesting without intravenous drip infusion after receiving the chemotherapy. Median time to treatment failure and overall survival time were 1.9 months [95% confidence interval (CI) 1.3–2.5 months] and 4.6 months (95% CI 3.9–5.3 months), respectively. Major grade 3 or 4 adverse events were anorexia (26%), neutropenia (26%), and anemia (22%). Conclusion The treatment regimen of 5-FU-based chemotherapy for advanced gastric cancer with severe peritoneal metastasis was feasible, but its efficacy was not sufficient. |
| abstractGer |
Background Treatment with an oral fluoropyrimidine plus cisplatin is widely used for advanced gastric cancer, but patients with severe peritoneal metastasis often cannot tolerate such treatment, due to inadequate oral intake or massive ascites. The aim of this study was to assess the efficacy and safety of systemic chemotherapy for advanced gastric cancer with severe peritoneal metastasis. Methods The cases of 92 patients with advanced gastric cancer and severe peritoneal metastasis who received first-line chemotherapy at our hospital between May 2001 and February 2007 were retrospectively analyzed. Severe peritoneal metastasis was defined as massive ascites or inadequate oral intake due to peritoneal dissemination. Inadequate oral intake was defined as having required an intravenous drip infusion. Results All 92 patients received 5-fluorouracil (5-FU)-based chemotherapy; 40 of the patients had massive ascites, 34 had inadequate oral intake, and the remaining 18 had both conditions. Among the 86 patients having assessable ascites, 23 (27%) patients showed an improvement in ascites. Of the 52 patients with inadequate oral intake, 17 (33%) patients improved to the point of ingesting without intravenous drip infusion after receiving the chemotherapy. Median time to treatment failure and overall survival time were 1.9 months [95% confidence interval (CI) 1.3–2.5 months] and 4.6 months (95% CI 3.9–5.3 months), respectively. Major grade 3 or 4 adverse events were anorexia (26%), neutropenia (26%), and anemia (22%). Conclusion The treatment regimen of 5-FU-based chemotherapy for advanced gastric cancer with severe peritoneal metastasis was feasible, but its efficacy was not sufficient. |
| abstract_unstemmed |
Background Treatment with an oral fluoropyrimidine plus cisplatin is widely used for advanced gastric cancer, but patients with severe peritoneal metastasis often cannot tolerate such treatment, due to inadequate oral intake or massive ascites. The aim of this study was to assess the efficacy and safety of systemic chemotherapy for advanced gastric cancer with severe peritoneal metastasis. Methods The cases of 92 patients with advanced gastric cancer and severe peritoneal metastasis who received first-line chemotherapy at our hospital between May 2001 and February 2007 were retrospectively analyzed. Severe peritoneal metastasis was defined as massive ascites or inadequate oral intake due to peritoneal dissemination. Inadequate oral intake was defined as having required an intravenous drip infusion. Results All 92 patients received 5-fluorouracil (5-FU)-based chemotherapy; 40 of the patients had massive ascites, 34 had inadequate oral intake, and the remaining 18 had both conditions. Among the 86 patients having assessable ascites, 23 (27%) patients showed an improvement in ascites. Of the 52 patients with inadequate oral intake, 17 (33%) patients improved to the point of ingesting without intravenous drip infusion after receiving the chemotherapy. Median time to treatment failure and overall survival time were 1.9 months [95% confidence interval (CI) 1.3–2.5 months] and 4.6 months (95% CI 3.9–5.3 months), respectively. Major grade 3 or 4 adverse events were anorexia (26%), neutropenia (26%), and anemia (22%). Conclusion The treatment regimen of 5-FU-based chemotherapy for advanced gastric cancer with severe peritoneal metastasis was feasible, but its efficacy was not sufficient. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER |
| container_issue |
1 |
| title_short |
First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer |
| url |
https://dx.doi.org/10.1007/s10120-011-0056-y |
| remote_bool |
true |
| author2 |
Nakajima, Takako Eguchi Nakamura, Kenichi Takashima, Atsuo Kato, Ken Hamaguchi, Tetsuya Yamada, Yasuhide Shimada, Yasuhiro |
| author2Str |
Nakajima, Takako Eguchi Nakamura, Kenichi Takashima, Atsuo Kato, Ken Hamaguchi, Tetsuya Yamada, Yasuhide Shimada, Yasuhiro |
| ppnlink |
SPR009286586 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s10120-011-0056-y |
| up_date |
2024-07-04T01:35:12.335Z |
| _version_ |
1803610396910682114 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009317430</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20201124064103.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2011 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10120-011-0056-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009317430</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10120-011-0056-y-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Iwasa, Satoru</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Treatment with an oral fluoropyrimidine plus cisplatin is widely used for advanced gastric cancer, but patients with severe peritoneal metastasis often cannot tolerate such treatment, due to inadequate oral intake or massive ascites. The aim of this study was to assess the efficacy and safety of systemic chemotherapy for advanced gastric cancer with severe peritoneal metastasis. Methods The cases of 92 patients with advanced gastric cancer and severe peritoneal metastasis who received first-line chemotherapy at our hospital between May 2001 and February 2007 were retrospectively analyzed. Severe peritoneal metastasis was defined as massive ascites or inadequate oral intake due to peritoneal dissemination. Inadequate oral intake was defined as having required an intravenous drip infusion. Results All 92 patients received 5-fluorouracil (5-FU)-based chemotherapy; 40 of the patients had massive ascites, 34 had inadequate oral intake, and the remaining 18 had both conditions. Among the 86 patients having assessable ascites, 23 (27%) patients showed an improvement in ascites. Of the 52 patients with inadequate oral intake, 17 (33%) patients improved to the point of ingesting without intravenous drip infusion after receiving the chemotherapy. Median time to treatment failure and overall survival time were 1.9 months [95% confidence interval (CI) 1.3–2.5 months] and 4.6 months (95% CI 3.9–5.3 months), respectively. Major grade 3 or 4 adverse events were anorexia (26%), neutropenia (26%), and anemia (22%). Conclusion The treatment regimen of 5-FU-based chemotherapy for advanced gastric cancer with severe peritoneal metastasis was feasible, but its efficacy was not sufficient.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastric cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peritoneal metastasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ascites</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oral intake</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakajima, Takako Eguchi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakamura, Kenichi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takashima, Atsuo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kato, Ken</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamaguchi, Tetsuya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamada, Yasuhide</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shimada, Yasuhiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Gastric Cancer</subfield><subfield code="d">Springer-Verlag, 2002</subfield><subfield code="g">15(2011), 1 vom: 15. Mai, Seite 21-26</subfield><subfield code="w">(DE-627)SPR009286586</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2011</subfield><subfield code="g">number:1</subfield><subfield code="g">day:15</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:21-26</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10120-011-0056-y</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2011</subfield><subfield code="e">1</subfield><subfield code="b">15</subfield><subfield code="c">05</subfield><subfield code="h">21-26</subfield></datafield></record></collection>
|
| score |
7.4028435 |